Here are six updates from gastroenterology companies and practices from the past week:
Tucson-based University of Arizona researchers have identified a biomarker that appears in patients before they develop stomach cancer.
In Wisconsin, Epic and Exact Sciences are decreasing COVID-19 test turnaround time by inputting results directly into Epic's MyChart program.
CMS issued a proposal that declined to cover the first FDA-approved blood-based colorectal cancer screening test, but created a guideline for still-in-development tests to earn approval.
Gastroenterology-focused Dr. Reddy's Laboratories was the victim of a cyberattack.
Using a noninvasive test to screen for colorectal cancer when a patient turned 45 years old added life years and decreased CRC incidence compared to starting screening when a patient turned 50 years old.
COVID-19 patients with gastrointestinal symptoms had higher admission rates to hospitals and intensive care units and higher intubation rates than those without GI symptoms, according to a poster presented at ACG 2020, Oct. 23-28.